Mycoplasma genitalium (also known as MG[3],Mgen, or since 2018, Mycoplasmoides genitalium[1]) is a sexually transmitted,[4] small and pathogenicbacterium that lives on the mucousepithelial cells of the urinary and genital tracts in humans.[5] Medical reports published in 2007 and 2015 state that Mgen is becoming increasingly common.[6][7] Resistance to multiple antibiotics, including the macrolideazithromycin, which until recently was the most reliable treatment, is becoming prevalent.[6][8] The bacterium was first isolated from the urogenital tract of humans in 1981,[9] and was eventually identified as a new species of Mycoplasma in 1983.[2] It can cause negative health effects in men and women. It also increases the risk for HIV spread[10] with higher occurrences in those previously treated with the azithromycinantibiotics.[6][11]
^Weinstein SA, Stiles BG (1 January 2012). "Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium". Expert Review of Anti-infective Therapy. 10 (4): 487–499. doi:10.1586/eri.12.20. ISSN1478-7210. PMID22512757. S2CID207218803.
^World Health Organization (WHO). Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Switzerland: World Health Organization 2013
^Barberá M, et al. Mycoplasma genitalium macrolide and fluoroquino-lone resistance: prevalence and risk factors among a 2013–2014 cohort of patients in Barcelona Sexually Transmitted Diseases: Spain, 2017; In Press